المؤلفون: Makoto Ito, Masahiro Kamata, Hideaki Uchida, Shota Egawa, Saki Fukaya, Kotaro Hayashi, Atsuko Fukuyasu, Takamitsu Tanaka, Takeko Ishikawa, Yayoi Tada

المصدر: Journal of Cutaneous Immunology and Allergy, Vol 6, Iss 5, Pp 168-171 (2023)

مصطلحات موضوعية: atopic dermatitis, biologics, dupilumab, Janus kinase, upadacitinib, Dermatology, RL1-803, Immunologic diseases. Allergy, RC581-607

الوصف: Abstract Janus kinase (JAK) inhibitors are efficacious for atopic dermatitis (AD). However, some patients receiving JAK inhibitors develop acne, especially younger patients, or herpes zoster, especially elderly patients, and desire to switch to dupilumab. We experienced two patients with immediate exacerbation of AD after switching from upadacitinib to dupilumab, and herein report these cases. This phenomenon is attributed to the difference in elimination half‐life of the two drugs and a slower onset of efficacy of dupilumab than upadacitinib. When switching from a JAK inhibitor to dupilumab, short‐term concomitant use, intensifying topical treatment, and/or rescue with cyclosporine should be considered.

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/2574-4593Test

الوصول الحر: https://doaj.org/article/4b139843692745c887fbbfb2d450e943Test

المؤلفون: Makoto Ito, Masahiro Kamata, Takeko Ishikawa, Hideaki Uchida, Shoya Suzuki, Ryosuke Takeshima, Ayu Watanabe, Itsumi Mizukawa, Shota Egawa, Saki Fukaya, Kotaro Hayashi, Atsuko Fukuyasu, Takamitsu Tanaka, Yayoi Tada

المصدر: Journal of Cutaneous Immunology and Allergy, Vol 6, Iss 5, Pp 152-158 (2023)

مصطلحات موضوعية: atopic dermatitis, dupilumab, Self‐Injection Assessment Questionnaire, Dermatology, RL1-803, Immunologic diseases. Allergy, RC581-607

الوصف: Abstract Dupilumab was approved for treating adult patients with atopic dermatitis (AD) refractory to topical therapy in Japan in April 2018, and self‐injection of dupilumab has been available since May 2019. Subcutaneous self‐injection of medication has benefits for patients and the healthcare system. However, anxiety about self‐injection, lack of confidence, and the complicated procedure could prevent initiating self‐injection. In this study, we assessed the experience of AD patients treated with dupilumab before and after introducing self‐injection, utilizing the Self‐Injection Assessment Questionnaire (SIAQ). Adult AD patients who received dupilumab by self‐injection and had been treated for more than 3 months after initiating self‐injection in our hospital from March 1, 2020, to June 19, 2021, were included in this study. Patients rated their perceptions about self‐injections using the SIAQ before the first self‐injection and 3 months after initiating self‐injection. Data were collected retrospectively from their charts. Data on 36 patients were analyzed. The mean age was 34.1 ± 11.5 years. Twenty patients used a prefilled auto‐injector, and the others used a prefilled syringe. Scores on self‐confidence and satisfaction with self‐injection significantly improved after introducing self‐injection. Feelings about injections improved in patients over 40 years and in those who felt anxious about self‐injection. A strong correlation in scores between satisfaction with self‐injection and the ease of use was observed. The results were not affected by clinical severity, gender, or device. Our results could encourage patients who dither to introduce self‐injection of dupilumab due to anxiety and/or lack of self‐confidence about self‐injection to initiate self‐injection.

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/2574-4593Test

الوصول الحر: https://doaj.org/article/bf8f9473143e4fcba7849cbbc62924caTest

المؤلفون: Hideaki Uchida, Masahiro Kamata, Shota Egawa, Mayumi Nagata, Saki Fukaya, Kotaro Hayashi, Atsuko Fukuyasu, Takamitsu Tanaka, Takeko Ishikawa, Takamitsu Ohnishi, Yayoi Tada

المصدر: Journal of Cutaneous Immunology and Allergy, Vol 5, Iss 1, Pp 17-21 (2022)

مصطلحات موضوعية: atopic dermatitis, calcineurin, dupilumab, interleukin‐4 receptor, tacrolimus, Dermatology, RL1-803, Immunologic diseases. Allergy, RC581-607

الوصف: Abstract Dupilumab demonstrated high efficacy and tolerable safety profiles in moderate‐to‐severe atopic dermatitis (AD) patients in clinical trials; however, certain patients suffer from facial redness, while obtaining good responses on the trunk and limbs to dupilumab in the real‐world setting. In our study, we investigated the effectiveness of tacrolimus ointment on facial lesions refractory to topical corticosteroid in patients with AD receiving dupilumab. This study included Japanese adult patients with moderate‐to‐severe AD who developed facial lesions during dupilumab treatment and whose facial lesions became refractory to topical corticosteroid treatment. Nine patients (one female, eight males) were included in this study. One patient newly developed facial erythema after initiating dupilumab. Facial lesions were refractory to dupilumab treatment in the other patients. Five of the nine patients showed improvement in EASI scores of head and neck by switching the facial treatment from topical corticosteroid to tacrolimus ointment. The patient who developed newly facial erythema showed improvement after applying tacrolimus ointment. Although we explored the predictors of effectiveness of tacrolimus ointment in patients with facial lesions during dupilumab treatment, no significant differences were observed in age, duration of dupilumab prior treatment, or prior head and neck EASI between patients who showed improvement after changing to tacrolimus and those who did not. Tacrolimus ointment is worth trying if facial lesions are refractory to topical corticosteroid.

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/2574-4593Test

الوصول الحر: https://doaj.org/article/4ff8145c25d9420e8d0dbf8c5954eff7Test

المؤلفون: Akiko JINNOUCHI, Kotaro HAYASHI, Makoto ITOU, Masahiro KAMATA, Saki FUKAYA, Satoe NUMAKURA, Takamitsu TANAKA, Takeko ISHIKAWA, Yayoi TADA, Yuko SASAJIMA, 伊藤 誠時, 多田 弥生, 林 耕太郎, 沼倉 里枝, 深谷 早希, 田中 隆光, 石川 武子, 笹島 ゆう子, 鎌田 昌洋, 陣内 晃子

المصدر: Skin Cancer. 2023, 38(2):130

المؤلفون: Emi SAKURAI, Kotaro HAYASHI, Masahiro KAMATA, Mitsuji SAITO, Saki FUKAYA, Shota EGAWA, Takamitsu TANAKA, Takeko ISHIKAWA, Yayoi TADA, Yuko SASAJIMA, 多田 弥生, 斉藤 光次, 林 耕太郎, 櫻井 恵海, 江川 昌太, 深谷 早希, 田中 隆光, 石川 武子, 笹島 ゆう子, 鎌田 昌洋

المصدر: Skin Cancer. 2023, 38(1):7

المؤلفون: Hideaki Uchida, Masahiro Kamata, Mayumi Nagata, Saki Fukaya, Kotaro Hayashi, Atsuko Fukuyasu, Takamitsu Tanaka, Takeko Ishikawa, Takamitsu Ohnishi, Kenjiro Mitsuhashi, Yayoi Tada

المصدر: Journal of Cutaneous Immunology and Allergy, Vol 4, Iss 5, Pp 143-145 (2021)

مصطلحات موضوعية: Dermatology, RL1-803, Immunologic diseases. Allergy, RC581-607

الوصف: This case report describes a 44‐year‐old male patient with atopic dermatitis who developed malignant lymphoma (diffuse large B‐cell lymphoma) during the dupilumab treatment.

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/2574-4593Test

الوصول الحر: https://doaj.org/article/fb071134a39642af923025fe7e044258Test

المؤلفون: Shintaro Takeoka, Masahiro Kamata, Carren Sy Hau, Mihoko Tateishi, Saki Fukaya, Kotaro Hayashi, Atsuko Fukuyasu, Takamitsu Tanaka, Takeko Ishikawa, Takamitsu Ohnishi, Yuko Sasajima, Shinichi Watanabe, Yayoi Tada

المصدر: Acta Dermato-Venereologica, Vol 98, Iss 5, Pp 506-511 (2018)

مصطلحات موضوعية: systemicplasmacytosis, IgG4-relateddisease, plasmacell, IgG4, Dermatology, RL1-803

الوصف: Systemic plasmacytosis is a rare skin disorder characterized by marked infiltration of plasma cells in the dermis. IgG4-related disease is pathologically characterized by lymphoplasmacytic infiltration rich in IgG4+ plasma cells, storiform fibrosis, and obliterative phlebitis, accompanied by elevated levels of serum IgG4. Reports of cases of systemic plasmacytosis with abundant infiltration of IgG4+ plasma cells has led to discussion about the relationship between systemic plasmacytosis and IgG4-related disease. This study examined IgG4+/IgG+ plasma cell ratios in 4 patients with systemic plasmacytosis and 12 patients with other skin diseases that show marked infiltration of plasma cells. Furthermore, we examined whether these cases met one of the pathological diagnostic criteria for IgG4-related disease (i.e. IgG4+/IgG plasma cells ratio of over 40%). Only one out of 4 patients with systemic plasmacytosis met the criterion. These results suggest that systemic plasmacytosis and IgG4-related disease are distinct diseases.

وصف الملف: electronic resource

العلاقة: https://www.medicaljournals.se/acta/content/html/10.2340/00015555-2909Test; https://doaj.org/toc/0001-5555Test; https://doaj.org/toc/1651-2057Test

الوصول الحر: https://doaj.org/article/0418fd105c264b4aa9af7f5ad5e045baTest

المؤلفون: Makoto Ito, MD, Masahiro Kamata, MD, PhD, Hideaki Uchida, MD, Mayumi Nagata, MD, Saki Fukaya, MD, Kotaro Hayashi, MD, PhD, Atsuko Fukuyasu, MD, Takamitsu Tanaka, MD, PhD, Takeko Ishikawa, MD, PhD, Takamitsu Ohnishi, MD, PhD, Yayoi Tada, MD, PhD

المصدر: JAAD International, Vol 1, Iss 2, Pp 91-92 (2020)

مصطلحات موضوعية: Dermatology, RL1-803

وصف الملف: electronic resource

العلاقة: http://www.sciencedirect.com/science/article/pii/S2666328720300286Test; https://doaj.org/toc/2666-3287Test

الوصول الحر: https://doaj.org/article/59cc05963786415e9ed73f2914ef49d7Test

المؤلفون: Saki Fukaya, Masahiro Kamata, Tomoko Kasanuki, Makoto Yokobori, Shintaro Takeoka, Kotaro Hayashi, Takamitsu Tanaka, Atsuko Fukuyasu, Takeko Ishikawa, Takamitsu Ohnishi, Satoshi Iimuro, Shinichi Watanabe, Yayoi Tada

المصدر: Acta Dermato-Venereologica, Vol 99, Iss 12, Pp 1178-1179 (2019)

مصطلحات موضوعية: bimatoprost, rhododendrol, leukoderma, depigmentation, repigmentation, melanocyte, Dermatology, RL1-803

الوصف: Abstract is missing (Short communication)

وصف الملف: electronic resource

العلاقة: https://www.medicaljournals.se/acta/content/html/10.2340/00015555-3299Test; https://doaj.org/toc/0001-5555Test; https://doaj.org/toc/1651-2057Test

الوصول الحر: https://doaj.org/article/49ddc98cde2546e0aa8e63bb311f9f4cTest

المؤلفون: Hideaki Uchida, Masahiro Kamata, Ayu Watanabe, Ai Agematsu, Mayumi Nagata, Saki Fukaya, Kotaro Hayashi, Atsuko Fukuyasu, Takamitsu Tanaka, Takeko Ishikawa, Takamitsu Ohnishi, Yayoi Tada

المصدر: Acta Dermato-Venereologica, Vol 99, Iss 7, Pp 675-676 (2019)

مصطلحات موضوعية: atopic dermatitis, alopecia areata, dupilumab, IL-4, IL-13, IL-4Rα, Dermatology, RL1-803

وصف الملف: electronic resource

العلاقة: https://www.medicaljournals.se/acta/content/html/10.2340/00015555-3183Test; https://doaj.org/toc/0001-5555Test; https://doaj.org/toc/1651-2057Test

الوصول الحر: https://doaj.org/article/0e78ee805af241199afc48ee26f42d6cTest